Sign inJoin
Company / Finance

AEON Biopharma, Inc.

AEON · NYSE AMERICAN

AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.

FollowAdd to WatchlistAsk Question
NYSE AMERICANAEONCoverage BootstrapBiotechnologyBiosimilarsTherapeutic Neurotoxin
Latest ReportMay 14, 2026AEON Biopharma: the BOTOX biosimilar bet running on a Q3 cash runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.

Sign in as admin